Financials • Specialty Insurers
$45.48 ▲ +1.18
(+2.66%)
MKT CAP: $1.39B • VOL: 4.40M
52W L $43 52W H $79
STC // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $2.92B | $2.49B | $2.21B |
| YoY Revenue Growth % | +17.3% | +12.6% | — |
| Gross Profit | $1.29B | $1.10B | $973.4M |
| Gross Margin % | 44.0% | 44.0% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $136.3M | $86.5M | $35.9M |
| Operating Margin % | 4.7% | 3.5% | 1.6% |
| Net Income (GAAP) | $115.5M | $73.3M | $30.4M |
| EBITDA (Normalized) | $241.5M | $176.2M | $115.6M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $205.7M | $135.6M | $83.0M |
| Capital Expenditures (CapEx) | $131.5M | $112.1M | $99.6M |
| Free Cash Flow (FCF) | $74.2M | $23.5M | -$16.5M |
| FCF Margin % | 2.5% | 0.9% | -0.7% |
| Return on Invested Capital (ROIC %) | 5.3% | 3.8% | 1.8% |
| Cash & Short-Term Equivalents | $321.8M | $216.3M | $292.0M |
| Total Debt (Short + Long Term) | $721.1M | $593.6M | $621.2M |
| Total Stockholders' Equity | $1.64B | $1.40B | $1.27B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR STC.